Table 2.
Oncogene mutations identified in next generation sequencing analysis of 85 PCC/PGL/HNPGL.
| Tumour ID | Clinical diagnosis | Type of tumour | Gene | Codon change | Aminoacid change | Allele frequency |
|---|---|---|---|---|---|---|
| P19 | Phaeochromocytoma | PCC | HRAS | c.37G>C | G13R | 72% |
| P20 | Phaeochromocytoma | PCC | HRAS | c.182A>G | Q61R | 36% |
| P21 | Phaeochromocytoma | PCC | HRAS | c.182A>G | Q61R | 27% |
| P22 | Phaeochromocytoma | PCC | HRAS | c.182A>G | Q61R | 40% |
| P23 | Phaeochromocytoma | PCC | HRAS | c.182A>G | Q61R | 50% |
| P24 | Phaeochromocytoma | PCC | HRAS | c.182A>G | Q61R | 26% |
| P25 | Phaeochromocytoma | PCC | BRAF | c.1799T>A | V600E | 10% |
| P26 | Phaeochromocytoma | PCC | TP53 | c.1010G>A | R337H | 4% |
| P27 | Phaeochromocytoma | PCC | TP53 | c.1010G>A | R337H | 21% |